PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS

Recurrent glioblastoma patients achieving response to bevacizumab combination therapy have clinical improvement and prolonged survival. High gene-expression of angiotensinogen (AGT) is associated with a poor response to bevacizumab combination therapy. Because AGT gene-expression is epigenetically r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Urup, Thomas, Gillberg, Linn, Kaastrup, Katja, Schuang Lü, Maja, Regner Michaelsen, Signe, Larsen, Vibeke A, Jarle Christensen, Ib, Broholm, Helle, Lassen, Ulrik, Grønbæk, Kirsten, Skovgaard Poulsen, Hans
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Molecular Pathology and Classification - Adult and Pediatric
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846921/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.624
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares